A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
Key Inclusion Criteria:
Key Exclusion Criteria:
Aurora, Colorado 80045, United States
Kansas City, Kansas 66160, United States
Houston, Texas 77030, United States
Richmond, Virginia 23298, United States
Nedlands, Western Australia 6009, Australia
Goettigen, Lower Saxony 37099, Germany
Modena, 1355 - 41126, Italy
Ichikawa-shi, Chiba 272-0827, Japan
Shinjuku-Ku, Tokyo-To 160-8582, Japan